Treatment Of Diabetes Is Different For Men And Women.
Widely utilized diabetes drugs have exceptional effects on men's and women's hearts, a young study suggests. Researchers examined how three commonly prescribed treatments for type 2 diabetes specious 78 patients who were divided into three groups. One group took metformin alone, the sec group took metformin plus rosiglitazone (sold under the trade mark name Avandia) and the third group took metformin plus Lovaza, a type of fish oil maleact.icu. Metformin reduces blood sugar film by the liver and improves insulin sensitivity.
Rosiglitazone also improves insulin kind-heartedness and moves free fatty acids out of the blood. Lovaza lowers blood levels of another font of fat called triglycerides. The researchers found that the drugs had very conflicting and sometimes opposite effects on the hearts of men and women, even as the drugs controlled blood sugar equally well in both genders continue reading. The meditate on appears in the December issue of the American Journal of Physiology - Heart and Circulatory Physiology.
Showing posts with label metformin. Show all posts
Showing posts with label metformin. Show all posts
Monday 14 January 2019
Saturday 26 May 2018
Sulfonylurea Drugs Increase The Risk Of Heart Disease
Sulfonylurea Drugs Increase The Risk Of Heart Disease.
New experiment with shows that older kith and kin with type 2 diabetes who take drugs known as sulfonylureas to humiliate their blood sugar levels may face a higher risk for heart problems than their counterparts who memorandum of metformin. Of the more than 8500 people aged 65 or older with epitome 2 diabetes who were enrolled in the trial, 12,4 percent of those given a sulfonylurea drug experienced a essence attack or other cardiovascular event, compared with 10,4 percent of those who were started on metformin incoming. In addition, these middle problems occurred earlier in the course of treatment among those people taking the sulfonylurea drugs, the investigation showed.
The head-to-head comparison trial is slated to be presented Saturday at the American Diabetes Association annual converging in San Diego. Because the findings are being reported at a medical meeting, they should be considered beginning until published in a peer-reviewed journal proextenderusa.men. With type 2 diabetes, the body either does not forth enough of the hormone insulin or doesn't use the insulin it does produce properly.
In either case, the insulin can't do its job, which is to utter glucose (blood sugar) to the body's cells. As a result, glucose builds up in the blood and can bring havoc on the body. Metformin and sulfonylurea drugs - the latter a savoir faire of diabetes drugs including glyburide, glipizide, chlorpropamide, tolbutamide and tolazamide - are often among the first medications prescribed to lower blood sugar levels in people with type 2 diabetes.
The findings are important, the researchers noted, partly because sulfonylurea drugs are commonly prescribed centre of the along in years to lower blood glucose levels. In addition, cardiovascular infection is the leading cause of death among people with type 2 diabetes. For several reasons, however, the supplementary study on these medications is far from the final word on the issue.
For one, people who are started on the sulfonylureas as an alternative of metformin are often sicker to begin with, said Dr Spyros G Mezitis, an endocrinologist at Lenox Hill Hospital in New York City. Metformin cannot be prescribed to hoi polloi with sure kidney and heart problems. Both medications lower blood glucose levels, but go about it in clearly different ways.
New experiment with shows that older kith and kin with type 2 diabetes who take drugs known as sulfonylureas to humiliate their blood sugar levels may face a higher risk for heart problems than their counterparts who memorandum of metformin. Of the more than 8500 people aged 65 or older with epitome 2 diabetes who were enrolled in the trial, 12,4 percent of those given a sulfonylurea drug experienced a essence attack or other cardiovascular event, compared with 10,4 percent of those who were started on metformin incoming. In addition, these middle problems occurred earlier in the course of treatment among those people taking the sulfonylurea drugs, the investigation showed.
The head-to-head comparison trial is slated to be presented Saturday at the American Diabetes Association annual converging in San Diego. Because the findings are being reported at a medical meeting, they should be considered beginning until published in a peer-reviewed journal proextenderusa.men. With type 2 diabetes, the body either does not forth enough of the hormone insulin or doesn't use the insulin it does produce properly.
In either case, the insulin can't do its job, which is to utter glucose (blood sugar) to the body's cells. As a result, glucose builds up in the blood and can bring havoc on the body. Metformin and sulfonylurea drugs - the latter a savoir faire of diabetes drugs including glyburide, glipizide, chlorpropamide, tolbutamide and tolazamide - are often among the first medications prescribed to lower blood sugar levels in people with type 2 diabetes.
The findings are important, the researchers noted, partly because sulfonylurea drugs are commonly prescribed centre of the along in years to lower blood glucose levels. In addition, cardiovascular infection is the leading cause of death among people with type 2 diabetes. For several reasons, however, the supplementary study on these medications is far from the final word on the issue.
For one, people who are started on the sulfonylureas as an alternative of metformin are often sicker to begin with, said Dr Spyros G Mezitis, an endocrinologist at Lenox Hill Hospital in New York City. Metformin cannot be prescribed to hoi polloi with sure kidney and heart problems. Both medications lower blood glucose levels, but go about it in clearly different ways.
Sunday 10 July 2016
Obesity Getting Younger In The United States
Obesity Getting Younger In The United States.
Obese children who don't have strain 2 diabetes but lure the diabetes drug metformin while improving their intake and exercise habits seem to lose a bit of weight. But it isn't much more weight than kids who only fix the lifestyle changes, according to a new review of studies. Some evidence suggests that metformin, in society with lifestyle changes, affects weight loss in obese children. But the drug isn't favoured to result in important reductions in weight, said lead researcher Marian McDonagh.
Childhood rotundity is a significant health problem in the United States, with nearly 18 percent of kids between 6 and 19 years previous classified as obese. Metformin is approved by the US Food and Drug Administration to wine and dine type 2 diabetes in adults and children over 10 years old, but doctors have Euphemistic pre-owned it "off-label" to treat obese kids who don't have diabetes, according to background information included in the study.
McDonagh's party analyzed 14 clinical trials that included nearly 1000 children between 10 and 16 years old. All were overweight or obese. Based on matter in adults, burden reductions of 5 percent to 10 percent are needed to decrease the risk of serious trim problems tied to obesity, the researchers said. The additional amount of weight wasting among children taking metformin in the review, however, was less than 5 percent on average.
Obese children who don't have strain 2 diabetes but lure the diabetes drug metformin while improving their intake and exercise habits seem to lose a bit of weight. But it isn't much more weight than kids who only fix the lifestyle changes, according to a new review of studies. Some evidence suggests that metformin, in society with lifestyle changes, affects weight loss in obese children. But the drug isn't favoured to result in important reductions in weight, said lead researcher Marian McDonagh.
Childhood rotundity is a significant health problem in the United States, with nearly 18 percent of kids between 6 and 19 years previous classified as obese. Metformin is approved by the US Food and Drug Administration to wine and dine type 2 diabetes in adults and children over 10 years old, but doctors have Euphemistic pre-owned it "off-label" to treat obese kids who don't have diabetes, according to background information included in the study.
McDonagh's party analyzed 14 clinical trials that included nearly 1000 children between 10 and 16 years old. All were overweight or obese. Based on matter in adults, burden reductions of 5 percent to 10 percent are needed to decrease the risk of serious trim problems tied to obesity, the researchers said. The additional amount of weight wasting among children taking metformin in the review, however, was less than 5 percent on average.
Subscribe to:
Posts (Atom)